Xeris Biopharma Holdings, Inc. Balance Sheet
XERS / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
Xeris Biopharma Holdings, Inc. had $384M in total assets and $14M in shareholders' equity as of FY2025. Total debt was $220M against $111M in cash, resulting in $109M net debt.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $111.0M | $71.6M | $67.4M | $122.0M | $67.3M | $37.6M |
| Accounts Receivable | $51.0M | $40.4M | $39.2M | $30.8M | $17.5M | $6.9M |
| Inventory | $68.7M | $48.2M | $38.8M | $24.7M | $18.1M | $8.4M |
| Current Assets | $240.3M | $167.7M | $156.3M | $186.8M | $142.6M | $152.2M |
| PP&E (Net) | $4.9M | $5.6M | $6.0M | $5.5M | $6.6M | $6.7M |
| Goodwill | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $0 |
| Total Assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M | $159.2M |
| Current Liabilities | $109.6M | $100.4M | $95.2M | $73.6M | $79.0M | $28.2M |
| Total Debt | $220.3M | $232.1M | $190.9M | $187.1M | $88.1M | $87.0M |
| Shareholders' Equity | $13.7M | -$29.6M | -$6.8M | $33.8M | $95.2M | $33.8M |